The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma
Open accessThe DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.
Abstract
Cancer stem cells (CSCs) are the main culprits involved in therapy resistance and disease recurrence in colorectal carcinoma (CRC). Results using cell culture, animal models and tissues from patients with CRC suggest the indispensable roles of colorectal CSCs in therapeutic failure. Conventional therapies target proliferating and mature cancer cells, while CSCs are mostly quiescent and poorly differentiated, thereby they can easily survive chemotherapeutic insults. The aberrant activation of Wnt/β-catenin, Notch, Hedgehog, Hippo/YAP (Yes-associated protein) and phosphatidylinositol 3-kinase/protein kinase B facilitates CSCs with excessive self-renewal and therapy resistance property in CRC. CSCs survive the chemo-radiotherapies by escaping therapy mediated DNA damage via altering the cell cycle checkpoints, increasing DNA damage repair capacity and by an efficient scavenging of reactive oxygen species. Furthermore, dysregulations of miRNAs e.g., miR-21, miR-93, miR-203, miR-215, miR-497 etc., modulate the therapeutic sensitivity of colorectal CSCs by regulating growth and survival signalling. In addition, a reversible quiescent G0 state and the re-entering cell cycle capacity of colorectal CSCs can accelerate tumour regeneration after treatment. Moreover, switching to favourable metabolic signatures during a therapeutic regimen will add more complexity in therapeutic outcomes against CSCs. Therapeutic strategies targeting these underlying mechanisms of CSCs’ therapy resistance could provide a promising outcome, however, deep understanding and concerted research are necessary to design novel therapies targeting CSCs. To conclude, the understanding of these mechanisms of CSC in CRC could lead to the improved management of patients with CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While conventional therapies target rapidly proliferating and more differentiated cancer cells, CSCs are slow-growing or quiescent and poorly differentiated [70].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, CSCs can adapt in response to chemotherapy and radiotherapy by altering cell cycle checkpoints, by inducing cell cycle arrest (reversible quiescent G0 state), or by efficient scavenging of ROS [70].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation
Battista, S., Pentimalli, F., Baldassarre, G., Fedele, M., Fidanza, V., Croce, C. M., & Fusco, A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0977fje · Cited by 69 · cited 1×
“HMGA1is a master regulator in both CSCs [83,84] and normal embryonic stem cells [84,85].”
RetractedMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“For example, mutations in key signalling pathway molecules, the increased expression of anti-apoptotic proteins, the presence of quiescent and/or resistant tumour cells or the over-activation of drug efflux pumps are all potential causes of therapy failure [4,5].”
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“For example, mutations in key signalling pathway molecules, the increased expression of anti-apoptotic proteins, the presence of quiescent and/or resistant tumour cells or the over-activation of drug efflux pumps are all potential causes of therapy failure [4,5].”
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 4×
“The pharmacological intervention of ROS scavenging property in CSCs could significantly decrease their clonogenicity and resulted in increased in sensitization of cancer cells to radiotherapy [57].”
InfluentialPark, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272 · cited 2×
“These differential expressed miRNAs, such as miR-451, miR-429 and miR-155, are associated with the differentiation and EMT process in CSCs [65,66].”
miR-34a repression of SIRT1 regulates apoptosis
Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801613105 · Cited by 1,342 · cited 16×
“Interestingly, miR-34 regulates the expression of SIRT1, and therefore, could be utilized against SIRT1 [100,103].”
InfluentialColon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4
Todaro, M., Alea, M. P., Di Stefano, A. B., Cammareri, P., Vermeulen, L., Iovino, F., Tripodo, C., Russo, A., Gulotta, G., Medema, J. P., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.001 · Cited by 1,039 · cited 2×
“An increase of CD133+ tumour cells (CSCs’ phenotype) has been found after oxaliplatin treatment in xenotransplanted colon cancer cells [24].”
ABC transporters in cancer: more than just drug efflux pumps
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2789 · Cited by 1,018 · cited 1×
“These quiescent CSCs can re-enter the cell cycle after treatment and can accelerate tumour regeneration by activating cell growth and proliferative signalling pathways [11,81].”
Exploring the role of cancer stem cells in radioresistance
Baumann, M., Krause, M., & Hill, R. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2419 · Cited by 815 · cited 2×
“Furthermore, these CSCs are also resistant to radiotherapy [12].”
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801 · cited 1×
“The activation of the PI3K/AKT pathway is associated with cancer therapy-associated resistances in many human malignancies, including CRC [44].”
Cited by
Items 101–200 of 222
Kehagias, P., Kindt, N., Krayem, M., Najem, A., Agostini, G., Reina, E. A., Bregni, G., Sclafani, F., Journé, F., Awada, A. H., et al. (2022) · Cells · doi:10.3390/cells11223663 · Cited by 15
Chen, Y., Lu, C., Cheng, W., Kuo, K., Yu, C.-W. F., Ho, H.-N., Chen, H., & Pan, S. (2022) · BMC Cancer · doi:10.1186/s12885-022-10042-3 · Cited by 14
LOXL2 reduces 5-FU sensitivity through the Hedgehog/BCL2 signaling pathway in colorectal cancer
Qiu, Z., Qiu, S., Mao, W., Lin, W., Peng, Q., & Chang, H. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221139203 · Cited by 14
Wnt3a is a promising target in colorectal cancer
Tufail, M., & Wu, C. (2023) · Medical Oncology · doi:10.1007/s12032-023-01958-2 · Cited by 14
“The Wnt signaling pathway is incriminated in tumor cell growth [57, 58], apoptosis [59, 60], angiogenesis [61, 62], stemness [63, 64], and resistance to chemotherapy [65, 66] (Fig.”
BackgroundBanerjee, A., Deka, D., Kumar, M. M., Sun-Zhang, A., Bişgin, A., Christopher, C., Zhang, H., Sun, X., & Pathak, S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03200-x · Cited by 14
“Dysregulation of miRNAs, which regulate the expression of target genes to govern cellular growth and survival, may contribute to minimal chemotherapeutic response in colon cancer stem cells by influencing molecular mechanisms [42] as shown in Fig.”
BackgroundVegetal-Derived Bioactive Compounds as Multidrug Resistance Modulators in Colorectal Cancer
Quiñonero, F., Mesas, C., Peña, M., Cabeza, L., Perazzoli, G., Melguizo, C., Ortíz, R., & Prados, J. C. (2023) · Applied Sciences · doi:10.3390/app13042667 · Cited by 14
Luo, Q., Liu, P., Yu, P., & Qin, T. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10508-2 · Cited by 13
Claudin-6 increases SNAI1, NANOG and SOX2 gene expression in human gastric adenocarcinoma AGS cells
Medrano-González, P. A., Cruz-Villegas, F., del Carmen, A. A., Montaño, L. F., & Rendon‐Huerta, E. P. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07976-z · Cited by 13
“It is clear that cancer cells switch to the epithelial mesenchymal transition process and gain CSC pluripotency simultaneously, an event that led to a therapeutic resistance phenotype [56].”
BackgroundMicroRNA in adenoid cystic carcinoma (Review)
Li, Y., Gu, F., He, Y., Xiang, J., Huang, X., Wang, Y., & Chen, R. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5465 · Cited by 12
Chen, H., Chen, C., Liu, K.-W., Chen, T., Tian, Y., Kuo, Y., Li, W., Tsai, H.-H., Wu, L.-C., Yeh, C.-F., et al. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154158 · Cited by 11
Guo, Y., Hu, G. M., Tian, B., Ma, M., Long, F., & Chen, M. (2022) · Cancers · doi:10.3390/cancers14246218 · Cited by 11
Mafi, A., Hedayati, N., Milasi, Y. E., Kahkesh, S., Daviran, M., Farahani, N., Hashemi, M., Nabavi, N., Alimohammadi, M., Rahimzadeh, P., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155457 · Cited by 11
Extracellular vesicles and cancer stem cells: a deadly duo in tumor progression
Tayanloo-Beik, A., Eslami, A., Sarvari, M., Jalaeikhoo, H., Rajaeinejad, M., Nikandish, M., Faridfar, A., Rezaei–Tavirani, M., Mafi, A. R., Larijani, B. A., et al. (2024) · Oncology Reviews · doi:10.3389/or.2024.1411736 · Cited by 11
“This therapeutic approach has been put into trial in a number of cancers (colorectal cancer [318], testicular cancer [319], breast cancer [320], ovarian cancer [321], and lung cancer [154]).”
BackgroundCyclin-Dependent Kinases As Potential Targets for Colorectal Cancer: Past, Present and Future
Manohar, S. M. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0064 · Cited by 11
A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy
Bano, I., Malhi, M., Zhao, M., Giurgiulescu, L., Sajjad, H., & Kieliszek, M. (2022) · 3 Biotech · doi:10.1007/s13205-022-03162-x · Cited by 10
Kusumaningrum, A. E., Makaba, S., Ali, E., Singh, M., Fenjan, M. N., Rasulova, I., Misra, N., Al‐Musawi, S. G., & Alsalamy, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3906 · Cited by 10
“128,129 The efficacy of first ‐ , second ‐ , and third ‐ generation ABCB1 inhibitors is highly affinitive, but they may be even more potent.”
BackgroundZhang, R., Zhang, X., Zhang, W., Cui, W., Xiao, Y., Liu, L., Zhi, S., Feng, X., Liu, X., Shen, Y., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0134 · Cited by 10
Chen, B., Sun, H., Xu, S., & Mo, Q. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00448-6 · Cited by 10
“CSCs are the major culprits leading to a new level of complexity and the consequential therapy resistance and disease recurrence in CRC [18].”
BackgroundA potential requirement for Smad3 phosphorylation in Notch-mediated EMT in colon cancer
Clark, A. G., Bertrand, F. E., & Sigounas, G. (2023) · Advances in Biological Regulation · doi:10.1016/j.jbior.2023.100957 · Cited by 10
Peng, X., Zhang, T., Jia, X., Wang, T., Lin, H., Li, G., Li, R., & Zhang, A. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.10.002 · Cited by 9
Study Deciphering the Crucial Involvement of Notch Signaling Pathway in Human Cancers
Pandey, P., Khan, F., Singh, M., verma, A., Kumar, H., Mazumder, A., & Rakhra, G. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303261691231107113548 · Cited by 9
Cell-based immunotherapy in oesophageal cancer
Lahouty, M., Soleymanzadeh, A., Kazemi, S., Saadati-Maleki, H., Masoudi, S., Ghasemi, A., Kazemi, T., Mehranfar, S., & Fadaee, M. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2477077 · Cited by 9
“…subpopulation of cancer cells, termed cScs, is linked to clinical characteristics including drug resistance, self-renewing and tumour growth in ec [31,32]. cScs are regarded as the origin of tumour recurrence and metastasis. ehtesham et al. showed that expression of metastasis-associated genes is…”
Ye, M.-L., Li, S., Yin, Y., Li, K., Li, J., & Hu, B.-L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.817509 · Cited by 9
“However, little is known about the role of the stemness score in CRC, although cancer stem cells are the main culprits involved in CRC therapy resistance and disease recurrence (Zeuner et al., 2014; Das et al., 2020).”
BackgroundZahra, M., Zahra, U. B., Abrahamse, H., & George, B. P. A. (2025) · RSC Advances · doi:10.1039/d5ra07380d · Cited by 8
Research progress on the mechanism of exosome-mediated virus infection
Zhang, H., Liu, X., Shi, J., Su, X., Xie, J., Meng, Q., & Dong, H. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1418168 · Cited by 8
Jin, W., Su, L., You, H., Dong, Z., Liu, M., & Zhou, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2906226 · Cited by 8
PRMT1-catalyzed NUSAP1 methylation enhances Notch2 signaling and 5-FU resistance in gastric cancer
Jiang, S., Li, G., Peng, S., Chen, S., Pang, Y., Cui, H., & Wang, F. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07723-9 · Cited by 8
Christodoulou, S., Sotiropoulou, C. D., Vassiliu, P., Danias, Ν., Arkadopoulos, N. F., & Sideris, D. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129990 · Cited by 8
“The Hippo, Notch, and WNT/β-catenin signaling pathways are only a few of the many pathways that miRNAs control, and their participation in CRC is crucial [20,21].”
BackgroundZanon, A. B., Silva, A. O., Franco, N., Picon, R. V., Lenz, G., Lopez, P. L. D. C., & Filippi‐Chiela, E. C. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30517 · Cited by 8
“31 CD133 and CD44 are the most used markers for CSCs analysis in CRC, 32 – 35 been associated with cancer progression, 36 poor prognosis 37 and resistance to therapy.”
Yang, H., Cao, Y., Li, D., Li, F., Ma, J., Peng, S., & Liu, P. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0257 · Cited by 8
Wu, X., Ye, Y., Vega, K. J., & Yao, J. (2022) · Cancers · doi:10.3390/cancers14153740 · Cited by 8
Nie, X., Liu, J., Wang, D., Li, C., Teng, Y., Li, Z., Jia, Y., Wang, P., Deng, J., Li, W., et al. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s476647 · Cited by 7
Filipiak-Duliban, A., Brodaczewska, K. K., Majewska, A., & Kiéda, C. (2022) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-022-00685-8 · Cited by 7
“G0/G1 phase arrest also suggests the presence of quiescent cancer stem cells (Das et al. 2020); however, markers of the CSC phenotype, such as ALDH1 and CD133, were not induced in B16F10 spheroids (Fig.”
BackgroundCharacterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model
Ghiandai, V., Grassi, E., Gazzano, G., Fugazzola, L., & Persani, L. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03378-2 · Cited by 7
Tian, J., Zhang, L., La, X., An, Y., Fan, X., & Li, Z. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c03761 · Cited by 7
LGR5 Expression Predicting Poor Prognosis Is Negatively Correlated with WNT5A in Colon Cancer
Mehdawi, L. M., Ghatak, S., Chakraborty, P., Sjölander, A., & Andersson, T. (2023) · Cells · doi:10.3390/cells12222658 · Cited by 7
“…believe that the present observations point to and strengthen the idea that therapeutic mimicking of WNT5A signaling could—via impaired β -catenin signaling—be an attractive means to reduce the niche of colon cancer stem cells and thereby prolong recurrence-free survival of colon cancer patients.”
BackgroundChang, P.-K., Yen, I., Tsai, W.-C., & Lee, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-45630-1 · Cited by 6
“Both of Hippo and WNT/β-catenin pathways are involved in chemoresistance and disease recurrence in CRC 4 .”
BackgroundRagab, E. M., Gamal, D. M. E., Elnajjar, F. F., Elkomy, H. A., Ragab, M. A., Elantary, M. A., Basyouni, O. M., Moustafa, S. M., El-Naggar, S. A., & Elsherbiny, A. S. (2025) · Discover Oncology · doi:10.1007/s12672-025-01846-3 · Cited by 6
Zhang, J., Shen, J., Zeng, T., Gao, C., Sheng, B., Li, J., Zeng, W., Shen, J., Shen, C., Wang, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1739981 · Cited by 6
“In addition, colorectal cancer stem cells (CCSCs) play a central role in mediating chemoresistance (Das et al., 2020).”
Kallio, P., Bessone, C., Seyednasrollah, F., Brodkin, J., Lassila, M., Högström, J., González‐Loyola, A., Petrova, T. V., Haglund, C. H., & Alitalo, K. K. (2025) · Cancer Research · doi:10.1158/0008-5472.can-23-1851 · Cited by 6
“As tumor stem cells have been suggested to have enhanced DNA damage repair (DDR) capacity (37), we analyzed the expression of transcripts related to NHEJ, homologous recombination, and base excision repair (BER) in scRNA-seq data from the Apc Min/+ mice.”
Osei, G. Y., Adu‐Amankwaah, J., Koomson, S., Beletaa, S., Ahmad, M. K., Asiamah, E. A., Smith‐Togobo, C., & Razak, S. R. A. (2023) · Future Oncology · doi:10.2217/fon-2023-0426 · Cited by 6
Jin, W., Wang, J.-J., Feng, Y.-F., Chen, B., & Hu, Z.-H. (2025) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2025.100136 · Cited by 5
Qi, Y., Wang, A., Chen, S., & Chen, W. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01659-6 · Cited by 5
“Moreover, accumulating evidence indicates that CSCs play a critical role in chemotherapeutic resistance, leading to relapse and metastasis in ovarian cancer [26].”
Pleckstrin-2 promotes the progression of colorectal cancer via YTHDF2-mediated TYMS mRNA stability
Zhou, Q., Li, Y., Li, X., Zhang, S., Wang, Y., Li, Z., Wang, X., Li, Y., Li, J., Lu, C., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05782-x · Cited by 5
“CRC stem cells (CCSCs) are a group of cells in tumor tissues that have the characteristics of stem cells such as self-renewal, multi-directional differentiation and tumori - genesis, which account for the higher metastasis and invasion of CRC [32, 33].”
Varlı, M., Lee, E.-Y., Park, S., Yang, Y., Hillman, P. F., Zhou, R., Hur, J., Nam, S., & Kim, H. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.062 · Cited by 5
“Consequently, CRC stem cells exhibit resistance to treatments such as chemotherapy or radiation therapy and play an important role in the development of metastases (Das et al ., 2020; Lei et al ., 2021).”
The lncrnas: innovative multifunctional players of drug resistance in colorectal cancer
Maghsoudi, H., Rasoulzadeh, M., Abbastabar, M., Fazilat, A., Sheikhnia, F., Azizzadeh, B., Valilo, M., & Majidinia, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03951-3 · Cited by 5
“These specific cells possess the capacity to initiate tumors in vivo and exhibit resilience against conventional chemotherapy and radiation therapies [104].”
Affinity-Based Magnetic Nanoparticle Development for Cancer Stem Cell Isolation
Kuru, C. İ., Ulucan‐Karnak, F., Dayıoğlu, B., Şahinler, M., Şendemir, A., & Akgöl, S. (2024) · Polymers · doi:10.3390/polym16020196 · Cited by 5
“The development of effective and reliable treatment methods targeting cancer stem cells depends on the isolation and identification of these cells from cancer cell lines and tumor tissues [17,18].”
BackgroundQuintero, M., & Bangi, E. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113370 · Cited by 5
Shakhpazyan, N. K., Михалева, Л. М., Bedzhanyan, A. L., Владиславовна, Г. З., Mikhalev, A. I., Midiber, K. Y., Konyukova, A. K., Atiakshin, D., Buchwalow, I., Tiemann, M., et al. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673316839240829075650 · Cited by 4
Chen, Y., Zhao, J., Wang, S., Qi, T., Hussain, S. A., & Wu, B. (2025) · Bioimpacts · doi:10.34172/bi.31073 · Cited by 4
Huang, T., Lee, J. S., Klibanov, A. L., & He, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073914 · Cited by 4
“Although the origin of CSC remains unclear and controversy arises whether all cancers follow the CSC mode, growing evidence demonstrates that CSCs exist in a wide array of tumors, not only in leukemia [13,14] but also in most solid tumors including breast cancer [15], ovarian cancer [16], pancreatic cancer [17,18], co…”
BackgroundLobaric acid suppresses the stemness potential of colorectal cancer cells through mTOR / AKT
Pulat, S., Paguirigan, J. A., Gamage, C. D. B., Varlı, M., Zhou, R., Park, S., Hur, J., & Kim, H. (2025) · BioFactors · doi:10.1002/biof.70002 · Cited by 4
Evaluation of BMP-2 as a Differentiating and Radiosensitizing Agent for Colorectal Cancer Stem Cells
Mahmoudi, R., Afshar, S., Amini, R., Jalali, A., Saidijam, M., & Najafi, R. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230330085615 · Cited by 4
Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal CancerPreprint
Villarreal, O. E., Xu, Y., Tran, H., Machado, A. A., Prescod, D., Anderson, A., Minelli, R., Peoples, M., Martinez, A. H., Lee, H. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.22.634215 · Cited by 4
Río-Vilariño, A., García-Bautista, A., Cenigaonandia‐Campillo, A., Mateos‐Gómez, P. A., García‐García, L., Schlaepfer, M. I., García-Hernández, L., del Puerto‐Nevado, L., Aguilera, O., Baños, N., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201032 · Cited by 3
“4 5–7 A key regulator of CSC traits is the Hippo signaling pathway, a highly conserved tumor suppressor cascade that limits cell proliferation and promotes apoptosis in normal tissues.”
Repurposing dihydroartemisinin as a novel anticancer agent against colorectal cancer stem cells
Wu, M., Sung, C., Kung, F., Guh, J., Su, Y., & Hsu, L. (2025) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3552 · Cited by 3
“CSCs are generally considered the main cause of therapy resistance in CRC [17].”
Jing, Y., Yang, N., Yu, S.-X., Qi, H., Yu, T., Chen, X., Wei, S., Zou, W., & Wang, J. (2025) · Stem Cells International · doi:10.1155/sci/7889271 · Cited by 3
“A key contributor to this malignant progression is a distinct subpopulation of cells known as cancer stem cells (CSCs), which exhibit self-renewal capabilities, resistance to conventional therapies, and are primarily responsible for tumor initiation and dissemination [3 – 6].”
Zănoagă, O., Braicu, C., Nutu, A. M., Berindan‐Neagoe, I., & Bender, A. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03682-x · Cited by 4
“Also, ECM interactions with integrins can activate FAK signaling, further promoting cancer cell survival and resistance to therapy [76].”
Oncogenic Role of Cancer Stem Cell LGR5 in Colorectal Cancer Progression
Kalkhajeh, S. G., Parsanezhad, A., Banoei, M., Vahidi, M., Kebria, M. M., Pezeshkian, Z., & Peyravian, N. (2021) · Canadian Journal of Medicine · doi:10.33844/cjm.2021.60609 · Cited by 3
miR-141-3p Enhanced Radiosensitivity of CRC Cells
Peng, L., Li, P., & Peng, Z. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230504144758 · Cited by 3
Hassan, S., Mirza, T., Khatoon, A., Bukhari, U., Shaikh, F., & Karim, A. (2024) · BMC Cancer · doi:10.1186/s12885-024-12925-z · Cited by 2
“Cancer stem cells (CSCs) have been established to have tumourigenic potential and are considered to contribute to therapy resistance and progression of CRC after the surgical resection of primary growth [12].”
BackgroundHu, J. X., Zhang, G., Yang, S., Shen, X., Zhou, M. R., Huang, L.-S., & Lan, H.-M. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i12.112366 · Cited by 2
“Dysregulation of Hippo-YAP signaling has been implicated in a wide range of cancers, including liver, colorectal, and biliary tract cancers[12,13].”
Yan, W., Li, Z., Kang, L., Xue, J., Wei, X., Liu, L., Liang, H., Yang, X., Liu, J., & Liu, D. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c05100 · Cited by 2
Lu, M., Liu, Y., Zhu, J., Shang, J., Bai, L., Jin, Z., Li, W., Hu, Y., Zheng, X., & Qian, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1514581 · Cited by 2
Potential Health Benefits of Fruits and Vegetables II
Mazzoni, L., Fernández, M. T. A., & Capocasa, F. (2023) · MDPI eBooks · doi:10.3390/books978-3-0365-8516-1 · Cited by 2
Understanding and Targeting the Colon Cancer Pathogenesis: A Molecular Perspective
Khan, I. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e20354 · Cited by 2
Valibeigi, B., Behzad‐Behbahani, A., Forouzanfar, M., Zarghampoor, F., & Jaafarinia, M. (2024) · Iranian Journal of Public Health · doi:10.18502/ijph.v53i3.15155 · Cited by 1
“Cancer stem cells are responsible for the initiation of tumors, development, metastasis, relapse, and resistance to treatments in CRC (11, 23, 24).”
BackgroundOkotel, M., & Huang, C. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025060830 · Cited by 1
Liu, J., Li, L., Zhang, L., Wang, W., Zheng, L., Kong, D., Wang, J., & Zhan, Y. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02477-5 · Cited by 1
“Emerging evidence indicates that cancer stem cells (CSCs)—a subpopulation of tumor cells with unlimited self-renewal and multipotent differentiation capacities—play a critical role in CRC initiation, progression, metastasis, and resistance to therapy [12–14].”
Ulusu, F., Özel, S. S., Sarılmaz, A., & Ulusu, Y. (2026) · Journal of Sol-Gel Science and Technology · doi:10.1007/s10971-025-07078-9 · Cited by 1
“In colorectal adenocarcinoma, enhancing the sensitivity of cancer stem cells (CSCs) to reactive oxygen species (ROS) has shown promise as a therapeutic approach for improving treatment ef fi cacy and promoting recurrence-free survival [5, 6].”
Colorectal Cancer Stem Cells: Mechanisms of Resistance and Emerging Therapeutic Targeting Strategies
Alsaeedi, F. A. (2026) · Onco · doi:10.3390/onco6020026 · Cited by 1
“For this reason, there is an urgent need for therapeutic strategies that specifically target and eradicate CRCSCs to achieve more durable clinical responses [37].”
InfluentialShen, J., Ma, Y., Wang, Y., Yang, M., Liang, T., & Guo, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118184 · Cited by 1
Karunakar, K. K., Philips, S., & Jayaprakash, N. (2026) · Discover Oncology · doi:10.1007/s12672-026-05497-w · Cited by 1
“…modalities, including surgical resection, cytotoxic chemotherapy, and radiotherapy, predominantly target rapidly proliferating tumor cells while inadequately eliminating quiescent In parallel, extrinsic cues within the tumor microenvironment play a pivotal role in sustaining CSC survival [6, 7].”
Cancer Stem Cells: Robust Features and Therapeutic Targets
Abu-Serie, M. M., & Sarhan, E. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_366 · Cited by 1
Stanniocalcin 2 Expression: A Significant Marker in the Prognosis of Colorectal Carcinoma
Zafar, S., Qamar, N., Shahid, M., Kamran, S., Sundus, S., & Aziz, Z. (2024) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v5i10.2016 · Cited by 1
Recent Update on Nanomedicine-Based Drug Targeting on Colon Cancer
Singh, V. K., Singh, V., & Tyagi, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-64668-4_14
Characteristics and therapy of advanced cancer diseases
Taghizadeh, H. (2021)
Li, Y., Huo, J., He, J., Ma, H., & Ma, X. (2020) · doi:10.21203/rs.3.rs-40559/v1
Spheroid Culture Models Imitating the Tumor Microenvironment of Renal and Melanoma CancerPreprint
Filipiak-Duliban, A., Brodaczewska, K. K., Majewska, A., & Kiéda, C. (2021) · Research Square · doi:10.21203/rs.3.rs-693762/v1
Cancer Stem Cells: Roles in Cancer Etiology
Islam, F. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_43-1
Self-citationPotential Biomarkers in Drug-Resistant Colorectal Cancer Cells
Li, D., Jin, L., Wang, M., Chen, J., Xia, C., & Chen, C. (2022) · Annals of Medical and Clinical Oncology · doi:10.29011/2833-3497.000142
Ning, B., Zhu, R., Xue, Y., Cao, Y., Jia, H., & Jia, B. (2023) · Research Square · doi:10.21203/rs.3.rs-2455922/v1
Ludikhuize, M. C. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1718
Plasticity of Cancer Stem Cell
Pillai, S., & Roy, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-3185-9_6
Introduction and Perspective in Carcinogenesis
Islam, F. (2023) · Springer eBooks · doi:10.1007/978-981-99-3185-9_1
Self-citationWang, F., Zhao, J., Zhang, C., Yang, B., Tian, T., Tian, M., Meng, N., Xie, W., Liu, G., Zhu, X., et al. (2023) · Discover Oncology · doi:10.1007/s12672-023-00779-z
Novel Therapeutic Targeting Cancer Stem Cell
Auwal, A., Rashel, K. M., Hossain, M. M., Hoque, M. A., Hossain, M. T., & Islam, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00105-0
Self-citationPerumal, M. K. K., Renuka, R. R., Srinivasan, G. P., & Jothinathan, M. K. D. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106797
The Prognostic Impact of SIRT1, STAT3, and YAP1 in Colorectal Carcinoma
Elkholy, S. S., Abdelbary, A., Elazab, D., Elkablawy, M. A., & Abdou, A. G. (2024) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001234
Zhou, X. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/2024.18867
ECM Signatures Reveal Quiescent Stem Cell Diversity in the Colonic NichePreprint
Hickey, S. E., Andreatta, M., Enright, C., Boucrot, E., Kiely, P., Cashman, S. B., Carmona, S. J., & McGourty, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632868
Identificação de RNAs não codificadores longos regulados pelo oncogene KRAS em câncer de pâncreas
Corrêa, T. B. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-09042025-160757
Construction of a Prognostic Model based on CSC-related Genes in Patients with Colorectal Cancer
Li, Z.-Y., Li, M., He, Y., Zheng, G., Chen, J., Guo, Y., Lian, Q., & Yue, C. (2025) · Journal of Cancer · doi:10.7150/jca.108188
“CSCs are capable of forming metastatic tumors owing to their proliferative capability[4], and it is acknowledged that CSCs are the main reasons resulting in treatment resistance and disease recurrence in CRC[29], which make them as promising therapeutic targets.”
Cancer Stem Cells: Roles in Cancer Etiology
Islam, F. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_43
Self-citationCancer Stem Cells Promote Tumorigenesis and Progression of Pancreatic Cancer Through Notch-1 Pathway
Zhang, S. (2025) · Cancer Investigation · doi:10.1080/07357907.2025.2592283
“In addition, it was also observed that CD44 þ CD24 þ cells started to proliferate at later time points, compared with bulk or CD44 - CD24 - cells, which is consistent with the notion that CD44 þ CD24 þ cells may represent CSCs in a quiescent state (40).”
Zhao, H., Fang, Y., Yang, N., Liu, G., Chen, X., & Zhao, J. L. (2025) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2025.100
Taib, N., Merhi, M., Inchakalody, V. P., Mestiri, S., Hydrose, S., Makni‐Maalej, K., Raza, A., Sahir, F., Azizi, F., Nizamuddin, P. B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26579675
Taib, N., Merhi, M., Inchakalody, V. P., Mestiri, S., Hydrose, S., Makni‐Maalej, K., Raza, A., Sahir, F., Azizi, F., Nizamuddin, P. B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26579696
Taib, N., Merhi, M., Inchakalody, V. P., Mestiri, S., Hydrose, S., Makni‐Maalej, K., Raza, A., Sahir, F., Azizi, F., Nizamuddin, P. B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26579678
Taib, N., Merhi, M., Inchakalody, V. P., Mestiri, S., Hydrose, S., Makni‐Maalej, K., Raza, A., Sahir, F., Azizi, F., Nizamuddin, P. B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26579684
Metadata
- Authors
- Das, P. K., Islam, F., & Lam, A. K.
- Affiliations
- University of Rajshahi (BD)
- Griffith University (AU)
- Corresponding author
- Islam, Farhadul
- Lam, Alfred K.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-06-03
- Volume
- 9
- Issue
- 6
- Pages
- 1392
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7348976
- OpenAlex
- W3033624893
- Cited by
- 210
- References
- 119
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 42 · 2023: 47 · 2022: 48 · 2021: 27 · 2020: 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Griffith Research Online (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- cancer stem cells, colorectal cancer, treatment resistance, Wnt/β-catenin signaling, Notch signaling, Hedgehog signaling, Hippo/YAP signaling, PI3K/Akt signaling, DNA repair, reactive oxygen species scavenging, cell cycle checkpoints, microRNA, metabolic reprogramming, chemoradiotherapy, self-renewal
- MeSH terms
- Animals, DNA Damage, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.